ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.


ABT-751 is an orally bioavailable tubulin-binding agent that is currently under clinical development for cancer treatment. In preclinical studies, ABT-751 showed antitumor activity against a broad spectrum of tumor lines including those resistant to conventional chemotherapies. In this study, we investigated the antivascular properties of ABT-751 in a rat subcutaneous tumor model using dynamic contrast-enhanced magnetic resonance imaging. A single dose of ABT-751 (30 mg/kg, intravenously) induced a rapid, transient reduction in tumor perfusion. After 1 h, tumor perfusion decreased by 57% before recovering to near pretreatment levels within 6 h. In contrast, ABT-751 produced little change in muscle perfusion at either time point. To further elucidate mechanisms of drug action at the cellular level, we examined the effects of ABT-751 on endothelial cells using an in-vitro assay. ABT-751, at concentrations corresponding to plasma levels achieved in vivo, caused endothelial cell retraction and significant loss of microtubules within 1 h. The severity of these morphological changes was dose-dependent but reversible within 6 h after the discontinuation of the drug. Taken together, these results show that ABT-751 is a tubulin-binding agent with antivascular properties. Microtubule disruption and morphological changes in vascular endothelial cells may be responsible, at least in part, for the dysfunction of tumor blood vessels after ABT-751 treatment.

DOI: 10.1097/CAD.0b013e32832c0acf

8 Figures and Tables


Citations per Year

77 Citations

Semantic Scholar estimates that this publication has 77 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Luo2009ABT751AN, title={ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.}, author={Yanping Luo and Vincent P. Hradil and David J. Frost and Saul Rosenberg and Gary Gordon and Sherry J. Morgan and Gerard D. Gagn{\'e} and Bryan F. Cox and Stephen K. Tahir and Gerard B. Fox}, journal={Anti-cancer drugs}, year={2009}, volume={20 6}, pages={483-92} }